LogicBio Reports First Quarter 2020 Financial Results and Provides Business Updates
“We remain committed to advancing LB-001 to the clinic for methylmalonic acidemia (MMA) as quickly as possible. We have had preliminary interactions with the FDA regarding their questions on our IND for LB-001 and plan to continue these interactions through the middle of the year. We look forward to providing an update on the anticipated timing for the initiation of our Phase 1/2 clinical trial for LB-001 after we complete these interactions,” said
Updates to Business Operations in Response to COVID-19
LogicBio has been actively monitoring the COVID-19 pandemic and its impact globally. LogicBio’s objectives have remained the same throughout the pandemic: to support the safety of its team members and their families and continue its research and development activities to develop genetic medicines that have the potential to durably treat rare diseases in pediatric patients with significant unmet medical need.
Since mid-March, the Company’s non-laboratory employees have been working remotely to comply with social distancing and “stay at home” orders as well as applicable guidelines from the
Business Highlights Include:
- Initiated work supporting collaboration with
Takedato leverage the GeneRide platform in Crigler-Najjar Syndrome. LogicBio and Takedaagreed to further research and develop LB-301, an investigational pediatric genome editing therapy based on LogicBio’s GeneRide technology for the treatment of CN. LB-301, utilizing the modularity of GeneRide, is expected to share several components with LB-001 to facilitate development.
- Moved headquarters to support platform development and capabilities expansion. The new lab and office space doubles the Company’s available space compared to its previous headquarters.
- Appointment of
Mark Enyedyto Board of Directors. Mr. Enyedybrings over 25 years of deep experience in biotech management, strategy, and corporate development, and currently serves as President and Chief Executive Officer of Immunogen, Inc.
First Quarter 2020 Financial Results
Three Months Ended
- R&D Expenses: Research and development expenses for the three months ended
March 31, 2020were $7.2 million, compared to $5.5 millionfor three months ended March 31, 2019. The increase was primarily due to an increase of approximately $0.7 millionrelated to external development and manufacturing expenses for the Company’s lead product candidate, LB-001, $0.4 millionin other research and development expenses related to general platform development and $0.6 millionin personnel-related costs due to an increase in headcount. While there may be fluctuations on a quarterly basis, the Company expects that its research and development costs will decrease over the next twelve months as it believes that it has already incurred a significant proportion of the LB-001 external development and manufacturing costs needed to bring LB-001 into clinical development.
- G&A Expenses: General and administrative expenses were
$3.2 millionfor the three months ended March 31, 2020, compared to $2.6 millionfor the three months ended March 31, 2019. The increase was primarily due to an increase in personnel-related costs due to an increase in headcount. The Company expects that general and administrative expenses will remain relatively consistent over the next twelve months, although there may be fluctuations on a quarterly basis.
- Net Loss: Net loss was
$9.5 million, or $0.41per share, for the three months ended March 31, 2020, compared to a net loss of $7.7 million, or $0.34per share, for the three months ended March 31, 2019.
- Cash Position and Financial Guidance: Cash and cash equivalents were
$43.2 millionas of March 31, 2020. The Company believes that its cash and cash equivalents as of March 31, 2020will enable the Company to fund operating expenses and capital expenditure requirements through the second quarter of 2021.
For more information, please visit www.logicbio.com.
Forward Looking Statements
This press release contains “forward-looking” statements within the meaning of the federal securities laws, including those related to the Company’s plans to resolve the FDA’s clinical hold on the IND for LB-001; the timing, progress and results of the Company’s research and development activities, including those related to the GeneRide technology platform; its plans for LB-301 in Crigler-Najjar; and the sufficiency of its cash, cash equivalents and investments to fund operating expenses and capital expenditure requirements. These are not statements of historical facts and are based on management’s beliefs and assumptions and on information currently available. They are subject to risks and uncertainties that could cause the actual results and the implementation of the Company’s plans to vary materially, including the risks associated with the initiation, cost, timing, progress and results of the Company’s current and future research and development activities and preclinical studies and potential future clinical trials. In particular, while the Company expects the COVID-19 pandemic to adversely affect its business operations and financial results, the extent of the impact on the Company’s ability to progress with its research, development, manufacturing and regulatory efforts, including the Company’s plans to resolve the clinical hold placed by the FDA on the IND for LB-001, and the value of and market for the Company’s common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in
|Condensed Consolidated Statements of Operations|
|(In thousands, except share and per share data)|
|Three Months Ended
|Research and development||7,173||5,486|
|General and administrative||3,192||2,632|
|Total operating expenses||10,365||8,118|
|LOSS FROM OPERATIONS||(9,344||)||(8,118||)|
|OTHER INCOME (EXPENSE), NET|
|Other expense, net||(6||)||—|
|Total other income (expense), net||(111||)||443|
|Loss before income taxes||(9,455||)||(7,675||)|
|Income tax provision||—||(22||)|
|Net loss per share—basic and diluted||$||(0.41||)||$||(0.34||)|
|Weighted-average common stock outstanding—basic and diluted||23,175,802||22,313,129|
|Condensed Consolidated Balance Sheets|
|March 31, 2020||December 31, 2019|
|Cash, cash equivalents and investments||$||43,153||$||50,647|
|Accounts payable, accrued expenses and other liabilities||$||15,042||$||13,373|
|TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY||$||48,749||$||55,660|
Associate Director, Investor Relations
Source: LogicBio Therapeutics